Personalized dosing of lutathera for neuroendocrine tumors
Part of Cancer clinical trials.
This trial tests a personalized way to give a radioactive drug called Lutathera to people with neuroendocrine tumors (NETs). The goal is to see if adjusting the dose based on how your body absorbs it can be more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a well-differentiated neuroendocrine tumor (NET) that started in your stomach, intestines, or pancreas.
- Your tumor must be at least 1.5 cm on a CT or MRI scan and show up brightly on a special PET scan.
- You should have a good performance status (able to do daily activities).
- Your neutrophil and platelet counts must be in the normal range.
- You cannot have had prior peptide-receptor radiotherapy (PRRT) treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how well Lutathera combined with ASTX727 can treat neuroendocrine tumors. It looks mainly at whether the combination can be given safely and effectively for people whose tumors have grown or not tolerated standard first treatment.
This Phase 2 study looks at whether giving Lutathera again (a second round) can control an intestinal neuroendocrine tumor (NET) that came back or progressed after the first treatment. It mainly targets adults whose scan shows tumors still take up the right “target” signal and who previously benefited for at least 12 months.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a radioactive drug called Lutathera for people with neuroendocrine tumors that are not in the stomach or intestines and can't be removed by surgery. The drug targets a specific receptor on the tumor cells to deliver radiation directly, which may help slow or shrink the cancer.
This trial tests a radioactive drug called Lutetium-177 Oxodotreotide (a type of PRRT) for people with advanced neuroendocrine tumors that have already been treated with other therapies and are still growing. The drug targets somatostatin receptors on tumor cells to deliver radiation directly to the cancer.
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.